Stevens Capital Management’s Anika Therapeutics ANIK Stock Holding History

Stevens Capital Management’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-6,486	Closed	-$350K	–	727
2017 Q4	$350K	Buy	6,486 +2,660	+70%	+$147K	0.01%	626
2017 Q3	$222K	Buy	+3,826	New	+$200K	0.01%	738
2017 Q2	–	Sell	-9,821	Closed	-$427K	–	840
2017 Q1	$427K	Buy	+9,821	New	+$469K	0.02%	617
2016 Q1	–	Sell	-10,467	Closed	-$399K	–	870
2015 Q4	$399K	Sell	10,467 -2,826	-21%	-$108K	0.02%	613
2015 Q3	$423K	Buy	13,293 +4,946	+59%	+$172K	0.02%	587
2015 Q2	$276K	Buy	+8,347	New	+$298K	0.01%	774
2014 Q3	–	Sell	-11,026	Closed	-$511K	–	981
2014 Q2	$511K	Buy	11,026 +2,912	+36%	+$130K	0.01%	655
2014 Q1	$333K	Buy	+8,114	New	+$302K	0.01%	762

Other funds holding ANIK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

AAM

AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return

Stevens Capital Management's ANIK Position: Q1 2018 in Review

Stevens Capital Management sold out of Anika Therapeutics (ANIK) in Q1 2018, closing a stake of 6,486 shares — an estimated $350K sold.

Stevens Capital Management first reported a position in ANIK in Q1 2014 and held it in 8 quarters. The position peaked at $511K in Q2 2014. 170 funds tracked by Wall St. Rank hold ANIK as of Q1 2018.

Stevens Capital Management reported no remaining Anika Therapeutics position as of Q1 2018 after selling out during the quarter.
Stevens Capital Management sold 6,486 Anika Therapeutics shares in Q1 2018, an estimated $350K.
Stevens Capital Management first reported a position in Anika Therapeutics in Q1 2014 and held it in 8 quarters.
Stevens Capital Management's Anika Therapeutics position peaked at $511K in Q2 2014.
170 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2018.

Based on Stevens Capital Management's 13F filing for Q1 2018, filed 8 May 2018.